The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | The impact of COPD and emphysema on mortality risk in lung cancer
Javier Zulueta, MD, Mount Sinai Morningside Hospital, New York, NY, comments on the impact of chronic obstructive pulmonary disease (COPD) and emphysema on chest CT scans for lung cancer. Patients with the aforementioned conditions are approximately three times more likely to develop lung cancer and do overall benefit from screening, where studies have demonstrated a reduction in mortality from lung cancer when screened early. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
